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Abstract
Background: Heterozygous loss-of-function mutations in the progranulin gene (GRN) lead to frontotemporal lobar
degeneration (FTLD) while the complete loss of progranulin (PGRN) function results in neuronal ceroid lipofuscinosis
(NCL), a lysosomal storage disease. Thus the growth factor-like protein PGRN may play an important role in lysosomal
degradation. In line with a potential lysosomal function, PGRN is partially localized and processed in lysosomes. In the
central nervous system (CNS), PGRN is like other lysosomal proteins highly expressed in microglia, further supporting an
important role in protein degradation. We have previously reported that cathepsin (Cat) D is elevated in GRN-associated
FTLD patients and Grn knockout mice. However, the primary mechanism that causes impaired protein degradation and
elevated CatD levels upon PGRN deficiency in NCL and FTLD remains unclear.
Methods: mRNA expression analysis of selected lysosomal hydrolases, lysosomal membrane proteins and autophagy-
related genes was performed by NanoString nCounter panel. Protein expression, maturation and in vitro activity of Cat D,
B and L in mouse embryonic fibroblasts (MEF) and brains of Grn knockout mice were investigated. To selectively
characterize microglial and non-microglial brain cells, an acutely isolated microglia fraction using MACS microbeads
(Miltenyi Biotec) conjugated with CD11b antibody and a microglia-depleted fraction were analyzed for protein expression
and maturation of selected cathepsins.
Results: We demonstrate that loss of PGRN results in enhanced expression, maturation and in vitro activity of Cat D, B
and L in mouse embryonic fibroblasts and brain extracts of aged Grn knockout mice. Consistent with an overall enhanced
expression and activity of lysosomal proteases in brain of Grn knockout mice, we observed an age-dependent
transcriptional upregulation of certain lysosomal proteases. Thus, lysosomal dysfunction is not reflected by transcriptional
downregulation of lysosomal proteases but rather by the upregulation of certain lysosomal proteases in an age-
dependent manner. Surprisingly, cell specific analyses identified early lysosomal deficits in microglia before enhanced
cathepsin levels could be detected in other brain cells, suggesting different functional consequences on lysosomal
homeostasis in microglia and other brain cells upon lack of PGRN.
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Conclusions: The present study uncovers early and selective lysosomal dysfunctions in Grn knockout microglia/
macrophages. Dysregulated lysosomal homeostasis in microglia might trigger compensatory lysosomal changes in other
brain cells.
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Background
Pathogenic mutations in the progranulin gene (GRN) are
genetically linked to frontotemporal lobar degeneration
(FTLD) and a rare adult-onset form of neuronal ceroid
lipofuscinosis (NCL) [1–4]. Haploinsufficiency caused by
non-sense and a few missense mutations result in GRN-as-
sociated FTLD (FTLD/GRN) [1, 2, 5–7] while homozygous
loss-of-function GRN mutation carriers, who completely
loose progranulin (PGRN) expression, develop NCL [3, 4].
Gene mutations causative for the different NCL forms are
mostly associated with the lysosomal degradation pathway
[8], indicating that PGRN may also be involved in lyso-
somal function. Indeed, Grn knockout mice are character-
ized by an increase of lysosomal proteins, NCL-like storage
material, lipofuscinosis and an accumulation of the autoph-
agy markers ubiquitin and p62 [3, 9–14]. Beside the genetic
link between PGRN and lysosomal disorders [3, 4], there is
also increasing evidence supporting lysosomal dysfunction
in FTLD [15]. Hallmarks of all FTLD/GRN patients are
cytoplasmic inclusions of hyperphosphorylated TAR DNA
binding protein (TDP)-43 co-localizing with ubiquitin and
p62 [16, 17]. Furthermore, FTLD/GRN patients show symp-
toms typically associated with NCL, like retinal thinning,
lipofuscin and NCL-like storage material deposits [18–21].
Finally, challenging lysosomes by starvation, sucrose treat-
ment, inhibition of vacuolar ATPase or alkalizing drugs
causes an increase in PGRN production [21–23]. PGRN is a
multifunctional complex glycosylated protein, which can be
secreted as a growth factor into the extracellular space
[24–26]. Secreted PGRN is also processed to granulin
peptides by several different proteases including matrix
metalloproteinases − 9 and − 14 [27, 28], a disintegrin
and metalloproteinase with thrombospondin motif 7
(ADAMTS-7) [29], neutrophil elastase, proteinase 3 [25, 30],
and intracellular by cathepsin L (Cat L) [31, 32]. Additionally,
PGRN can be transported to lysosomes using two distinct
transport pathways; one mediated by the sortilin receptor
[33] and the other one via complex formation with prosapo-
sin. Prosaposin is then transported to lysosomes by binding
to the mannose-6-phosphate receptor or the low density
lipoprotein receptor-related protein 1 [34]. Recent evi-
dence indicates that lysosomal localized PGRN [33, 35–
37] may function in lysosomal homeostasis and autoph-
agy [38–40]. Additionally, granulin peptides, which are
generated within lysosomes [31, 32, 41], might affect
the lysosomal function [38].
To further understand if and how the loss of PGRN
may cause lysosomal dysfunction we searched for
changes in protein expression, maturation and enzym-
atic activity of a subset of lysosomal cathepsins in micro-
glia and other brain cells. Microglia, which are the main
source of PGRN in the brain, showed a severe impair-
ment of lysosomal cathepsin expression and maturation
in the absence of PGRN whereas the remaining brain
cells showed increased cathepsin processing and matur-
ation. We therefore propose different effects on lyso-
somal function upon loss of PGRN in microglia and
other brain cells like astrocytes and neurons.
Methods
Animal experiments and mouse brain tissue
All animal experiments were performed in accordance
with local animal handling laws. Mice were sacrificed by
CO2 inhalation. Brain tissue was obtained from the
Grn−/− mouse strain generated by Kayasuga and col-
leagues [42].
Isolation of adult primary microglia, neurons and
astrocytes
Primary microglia were isolated from adult mouse brain
using MACS Technology (Miltenyi Biotec) according to
manufacturer’s instructions. Briefly, brain cortices were
dissected, and after removal of meninges dissociated by
enzymatic digestion using the Neural Tissue Dissoci-
ation Kit P (Miltenyi Biotec). CD11b-positive microglia
were magnetically labelled with CD11b MicroBeads,
loaded onto a MACS Column (Miltenyi Biotec) and sub-
jected to magnetic separation. Isolated microglia and the
microglia depleted fraction were snap frozen in liquid
nitrogen and stored at − 80 °C until further biochemical
analysis. To determine PGRN expression in different
brain cell types, microglial, neuronal and astrocytic cells,
the dissected mouse brain, after removal of meninges,
was dissociated by using the Adult Brain Dissociation
Kit (Miltenyi Biotec). A single cell suspension was gener-
ated according to the manufactures instructions with the
exception that the mouse brain was mechanically disso-
ciated by using in sequence, three fire-polished Pasteur
pipettes with decreasing tip diameters. The single cell
suspension of five mice were combined and separated in
three aliquots for isolating microglia cells (Anti-CD11b
MicroBeads, Miltenyi Biotec), astrocytes (Anti-ACSA-2
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MicroBeads, Miltenyi Biotec) and neurons (Neuron
Isolation Kit, Miltenyi Biotec) according to the manufac-
tures instructions. Isolated cells were snap frozen in
liquid nitrogen and stored at − 80 °C until further bio-
chemical analysis.
Generation and culturing of mouse embryonic fibroblasts
(MEF) lines
Ctsd−/− MEF were provided by Dr. Paul Saftig and
generated from the Ctsd knockout mouse strain [43].
For Grn−/− MEF, timed pregnant female of a heterozy-
gous Grn mating was sacrificed by CO2 inhalation, the
embryos (E15) were processed and MEF were separated
by digestion with trypsin-EDTA [44]. MEF cells with the
same genotype derived from littermates were pooled and
immortalized by serial (3 T3) passaging [44]. From im-
mortalized MEF either single cell clones were isolated or
pools were generated. For rescue of PGRN deficiency,
Grn−/− MEF were transfected with mGrn cloned into the
HindIII and XhoI site of pcDNA3.1 (Hygro+) and se-
lected with hygromycin B at 50 mg/mL (Invitrogen). Sin-
gle cell clones were analyzed for PGRN expression. MEF
were cultured in DMEM with Glutamax I (Invitrogen)
supplemented with 10% fetal calf serum (Invitrogen) and
penicillin/streptomycin (PAA Laboratories).
Quantitative NanoString nCounter gene expression assay
NanoString nCounter technology allows expression ana-
lysis of multiple genes from a single sample. We gener-
ated an nCounter panel for analyzing gene expression of
45 lysosomal and autophagy- related genes [45–48] and
5 housekeeping genes. Total RNA was extracted from al-
iquots of powdered mouse brain samples using QIAsh-
redder and RNeasy Mini Kit (Qiagen). 100 ng RNA per
brain was used for gene expression analysis. The Nano-
String panel measurement and evaluation was done at
Proteros Biostructures GmbH, Martinsried, Germany.
Gene expression levels in each sample were normalized
against the geometric mean of four housekeeping genes
including Cltc, Hprt, Pgk1 and Tubb5 using nSolver™
Analysis Software, version 3.0 (NanoString Technologies,
Inc.) Gusb was excluded because of significant changes
of expression in Grn−/− mice. Based on the normalized
gene expression levels of Grn−/− and Grn+/+ (n = 3), stat-
istical significance was determined by the unpaired,
two-tailed student’s t-test.
Quantitative real time PCR (qRT-PCR)
Approximately 10–20 mg of powdered mouse brain ho-
mogenates were subjected to total RNA preparation
using the QIAshredder and RNeasy Mini Kit (Qiagen)
according to manufacturer’s instructions. 2 μg of RNA
was reverse transcribed into cDNA using M-MLV re-
verse transcriptase (Promega) and oligo(dT) primers
(Life Technologies). The following primer sets from
Integrated DNA Technologies were used: mouse Ctsd
Mm.PT.53a.17202883 (Exon boundary 3 to 4), mouse
Ctsb Mm.PT.53a.7639164 (Exon boundary 4 to 5),
mouse Ctsl Mm.PT.58.9857472 (Exon boundary 7 to 8),
mouse App Mm00431827_m1 (Applied Biosystems) and
mouse Gapdh Mm.PT.39a.1 (Exon boundary 2 to 3).
cDNA levels were quantitatively determined in triplicates
using TaqMan assays on a 7500 Fast Real-Time-PCR Sys-
tem (Applied Biosystems). All cDNA levels were normal-
ized to Gapdh cDNA and relative transcription levels of
the respective sequences were analyzed using the com-
parative delta Ct method (7500 Software V2.0.5, Applied
Biosystems, Life Technologies).
Antibodies
The following primary antibodies were used for immuno-
blotting: mouse monoclonal anti-β-actin antibody (Sig-
ma-Aldrich; 1:10,000), mouse monoclonal anti-α-tubulin
antibody (Sigma-Aldrich; 1:5,000), goat anti-cathepsin D
(sc-20) antibody (Santa Cruz Biotechnology; 1:500), goat
anti-cathepsin B (AF965) antibody (R&D Systems; 0,1 μg/
ml), goat anti-cathepsin L (AF1515) antibody (R&D Sys-
tems; 1 μg/ml), goat anti-cathepsin S (M-19) antibody
(Santa Cruz Biotechnology; 1:200), rat anti-PGRN (8H10)
antibody (1:50) [18]; rabbit anti-GFAP antibody (Dako;
1:5,000), rabbit anti-Iba1 antibody (Dako; 1:1000), rabbit
anti-neuronal class III ß-Tubulin (Tuj1) antibody (BioLe-
gend; 1:10,000), rabbit anti-p62/SQSTM1 antibody (MBL;
1:1,000), mouse anti-ubiquitin (P4D1) antibody (Santa Cruz
Biotechnology; 1:1000), rabbit anti-APP (Y188) antibody
(Abcam, 1:2,000) rat monoclonal anti-mLamp1 antibody
clone 1D4B (developed by J. Thomas August, distributed
by Developmental Studies Hybridoma Bank, NICHD,
maintained by the University of Iowa, Department of Biol-
ogy; 1:200), goat polyclonal anti-saposin D antibody
(1:1,000) [49], and rabbit anti-LC3BB/MAP1LC3B antibody
(Novus Biologicals; 2 μg/ml). The following secondary anti-
bodies were used: horseradish peroxidase-conjugated don-
key anti-goat IgG (Santa Cruz Biotechnology; 1:5,000),
anti-mouse IgG (Promega; 1:10,000), anti-rabbit IgG (Pro-
mega; 1:20,000), goat anti-rat IgG + IgM (L +M) (Dianova;
1:5,000) and generated mouse anti-rat IgG2c (1:1,000).
Protein analysis and immunoblotting
For microglia, neurons and astrocytes cell pellets were
lysed in RIPA buffer [18] supplemented with protease in-
hibitor cocktail (Sigma-Aldrich) and phosphatase inhibi-
tor (Roche Applied Science) and centrifuged for 30 min,
15,000 x g, 4 °C. MEF cells were lysed in RIPA buffer
(150 mM NaCl, 50 mM TRIS pH 8.0; 0.1% SDS, 1%
NP40, 0.5% Sodiumdeoxycholat) supplemented with
Benzonase (Novagen), protease inhibitor cocktail (Sig-
ma-Aldrich) and phosphatase inhibitor (Roche Applied
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Science) and centrifuged for 30 min, 15,000 x g, 4 °C.
The protein concentration of the supernatant was deter-
mined using the BCA protein assay (Pierce, Thermo Sci-
entific) and equal amount of protein were separated by
SDS-PAGE and transferred onto polyvinylidene difluor-
ide membranes (Immobilon-P, Merck Millipore). For the
detection of C-terminal fragments (CTF) of the amyloid
precursor protein (APP) and saposin D the proteins
were transferred onto nitrocellulose membranes (Protran
BA85, GE Healthcare Lifesciences) and heated in PBS.
Proteins of interest were detected by the indicated primary
antibodies followed by horseradish peroxidase-conjugated
secondary antibodies and ECL (Amersham Western Blot-
ting Detection reagent, GE Healthcare Lifesciences) or
ECL Plus (Pierce ECL Plus Western Blotting Substrates,
Thermo Scientific). For the quantitatively analysis, images
were taken by a Luminescent Image Analyzer LAS-4000
(Fujifilm Life Science, Tokyo, Japan) and evaluated with
the Multi GaugeV3.0 software (Fujifilm Life Science,
Tokyo, Japan).
Cathepsin activity assay
MEF cell pellets or aliquots of powdered mouse brain
tissues were used for cathepsin D, B and L fluorescence
based activity assays (Abnova). The samples were ho-
mogenized in the appropriate lysis buffer provided by
the manufacturer and incubated for 10 min (MEF cell ly-
sates) or 20 min (brain lysates) on ice, followed by a
5 min (MEF cell lysates) or 20 min (brain lysates) centri-
fugation at 15,000 x g, 4 °C. The protein concentration
was determined by BCA protein assay (Pierce, Thermo
Scientific) and equal amounts of protein were used for
the activity assays. The assays were performed in black
96-well plates (FluoroNunc) at 37 °C for 20 min accord-
ing to the manufacturer’s protocol. Cleavage of the
quenched fluorescence substrate was continuously mea-
sured as increase of fluorescence signal by Fluoroskan
Ascent FL plate reader (Labsystems). The relative en-
zyme activity was calculated for a period of time with
linear substrate turnover.
Metabolic labeling and protein turn over
To analyze protein turnover, MEF at 70–80% of con-
fluency were starved for 1 h in methionine-, cysteine-
and serum-free minimal essential medium (Invitrogen)
and subsequently metabolically pulse-labeled with
18.5 MBq 35S-methionine/cysteine (Met-S35-label, Hart-
mann Analytic) in methionine-, cysteine- and serum free
medium for 1 h, followed by indicated chase periods in
the presence of a 5-fold excess of unlabeled methionine.
Cell lysates were prepared and labeled proteins were pre-
cipitated with 5% TCA for 1 h at 4 °C, followed by 30 min
centrifugation at 13,000 rpm, 4 °C. Pellets were washed
twice with 80% acetone, dried at RT and resuspended in
50 μl sample buffer. Remaining radioactive-labeled pro-
teins were measure in triplicates in liquid scintillation
counter (Tri-Carb 2810, Perkin Elmer).
Statistical analysis
For statistical analysis the unpaired, two-tailed student’s
t-test was performed when two groups of samples (wt
and ko) were compared, for comparison of more than
two groups, one-way ANOVA with Dunnett’s post hoc
test was used and statistical significance was set at *,
p < 0.05; **, p < 0.01; ***, p < 0.001; and ****, p < 0.0001.
Results
Subtle changes in lysosomal and autophagy-related gene
expression in total brain of Grn−/− mice
Accumulating evidence indicates that PGRN plays a crit-
ical role for lysosomal integrity and function. To obtain
insights into the role of PGRN in autophagic/lysosomal
protein degradation pathways we performed on whole
brain extract a NanoString based mRNA expression ana-
lysis of selected lysosomal and autophagy-related genes
[45] (Fig. 1a). Surprisingly, expression of only very few
genes was significantly altered in the brain of 6- and
12-month-old Grn−/− mice (Fig. 1a, b). Only eight genes,
among which are three genes encoding the lysosomal
membrane proteins Cd68, Cd63 and Lamp1, show a sig-
nificantly elevated expression in Grn−/− mice. Addition-
ally, the lysosomal hydrolases hexosaminidase subunit β
(Hexb) and cathepsin D (Ctsd) showed the strongest and
age-dependent increase in Grn−/− mice (Fig. 1b). However,
no general elevation of lysosomal and autophagy-related
gene expression regulated by transcription factor EB
(TFEB) [46, 50] was observed in Grn−/− mice brain. Thus,
although Grn−/− mice recapitulate important pathological
features of NCL, expression of lysosomal genes is not
overtly affected.
(See figure on previous page.)
Fig. 1 Minor alterations in expression of lysosomal and autophagy-related genes in brain of Grn−/− mice. a mRNA expression for 45 selected
genes associated with the lysosome-autophagy degradation pathway [45, 46] in brain of Grn+/+ (wt) and Grn−/− (ko) mice at 6 and 12 months of
age (for original data see Additional file 2). Genes are grouped by their function within these pathways or by their FTLD-association. Previously
identified TFEB targets are labeled by red boxes [46, 47]. N = 3 mice per group, notice the low expression differences between individual mice
and between 6- and 12-month-old mice. Trem2 and Atp6v0d2 were below the detection limit. b Fold change of gene expression which show at
least one significand change either at 6 or 12 months of age. Data were normalized to the corresponding mean value of Grn+/+ (wt) mice and
are shown as mean ± SD. For statistical analysis the unpaired, two-tailed student’s t-test was used (n = 3) (*, p < 0.05; **, p < 0.01; ***, p < 0.001)







Fig. 2 (See legend on next page.)
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Elevated cathepsin maturation and activity in PGRN
deficient mouse brain
We have previously shown that cathepsin D (CatD) is el-
evated in brain of young Grn−/− mice and that CatD ac-
cumulation further increases with age [18]. These
findings have been confirmed [12, 51], but the origin of
CatD increase remains mainly unclear and cannot sim-
ply be explained as a compensation phenomenon in re-
sponse to general reduced expression of lysosomal
enzymes (Fig. 1). To address whether elevated Ctsd
mRNA levels (Fig. 1b; Additional file 1: Figure S1) trans-
late into increased protein levels and result in enhanced
enzyme activity, we analyzed protein expression, matur-
ation and in vitro activity of CatD in brain of 3- and
20-month-old mice (Fig. 2b-e). To further monitor lyso-
somal activity in Grn−/− mice we also investigated pro-
tein expression, maturation and catalytic activity of two
additional cathepsins, namely CatB (Fig. 2f-i) and CatL
(Fig. 2j-m). Both lysosomal cysteine proteases have been
associated with PGRN metabolism. CatL might be directly
involved in lysosomal processing of PGRN into granulins
[31] and CatL and CatB cleave and inactivate the secretory
leucoprotease inhibitor (SLPI) which protects extracellular
PGRN from processing [52]. Maturation and activation of
most cathepsins follows a unified processing pathway gen-
erating active single and double chain variants (Fig. 2a)
(reviewed in [53]). In 3-month-old Grn−/− mice, CatD ex-
pression, maturation and activity was unchanged (Fig. 2b, c;
Additional file 1: Figure S1). In aged mice (20 months) ac-
tive single chain CatD (CatDsc) as well as further processed
heavy chain CatD (CatDhc) are about 4- to 5-fold increased
(Fig. 2d). This is accompanied by a 1.75-fold elevated pro-
teolytic activity in Grn−/− mice brain (Fig. 2e). In contrast
to the robust increase of the CatD protein levels, we could
only detect a 2-fold increase of mRNA (Additional file 1:
Figure S1) suggesting posttranscriptional regulatory mecha-
nisms. CatB and CatL are slightly elevated in young Grn−/−
mice (Fig. 2f, j) but no significant change in their catalytic
activity was observed (Fig. 2g, k). Their mRNA levels were
not altered (CatB) or only slightly elevated (CatL)
(Additional file 1: Figure S1). In aged Grn−/− mice, CatB
and CatL expression, processing and activity were elevated
(Fig. 2h, i, l, m; Additional file 1: Figure S1). Thus, against
the expectations that lysosomal activity might be de-
creased in Grn−/− mice, their proteolytic in vitro activity is
elevated in total brain lysates.
Increased activity of cathepsins in mouse embryonic
fibroblasts (MEF) lacking PGRN
MEF generated from Grn+/+ show a robust localization
of PGRN in lysosomes (Additional file 1: Figure S2a),
while MEF generated from Grn−/− littermates show an
increase of LAMP1 and an accumulation of saposin D,
which is in line with our previous observations in brains
of Grn−/− mice and FTLD/GRN patients [18] (Additional
file 1: Figure S2b). We next examined the in vitro activ-
ity and maturation of CatD, CatB and CatL in Grn−/−
and Grn+/+ MEF (Fig. 3). In Grn−/− MEF the overall
CatD level was 1.7-fold elevated. Moreover, CatDhc was
increased about eight fold whereas CatDsc expression
was not altered (Fig. 3a). The elevated protein level of
CatDhc is in line with a significantly enhanced in vitro
enzymatic activity (Fig. 3b). A second independent pool
of MEF Grn−/− as well as single cell clones additionally
confirmed altered maturation and elevated levels of CatDhc
(Additional file 1: Figure S2c, d). Similar to mouse brain,
CatB and CatL showed altered maturation (Fig. 3c, e) and a
robust increase of in vitro activity (Fig. 3d, f). Low amounts
of stably expressed PGRN were sufficient to rescue altered
maturation of CatD and to lower hyperactivity of cathep-
sins (Fig. 3g, Additional file 1: Figure S3a, b). Thus, MEF,
like total brain extract of Grn−/− mice, exhibit increased ca-
thepsin expression, maturation and in vitro activity. To in-
vestigate the functional consequences of enhanced
lysosomal activity we compared general protein degradation
in Grn−/− and Grn+/+ MEF. Newly synthesized proteins
were metabolically pulse labeled for one hour and chased
for indicated periods of time (Fig. 4a). The relative protein
turnover calculated by the percentage of remaining radiola-
beled protein was higher in Grn−/− MEF compared to
(See figure on previous page.)
Fig. 2 Altered protein expression, maturation and activity of cathepsins in brain of Grn−/− mice. a Schematic presentation of cathepsin maturation [53].
Cathepsins (Cat) are synthesized as an inactive pre-pro-form (pp), translocated into the endoplasmic reticulum (ER) by signal peptide (SP). After SP removal
the pro-form (p) becomes co-transitionally modified and is transported to lysosomes predominantly via the manose-6-phosphate pathway. With increasing
acidification, the pro-peptide is removed, either autocatalytically or by other enzymes, leading to an active single chain variant (sc, green). For most cathepsins
this sc-variant can be further proteolytically processed to a heavy (hc) and a light chain (lc), as long as hc and lc are linked by disulfide bridges or
hydrophobic interaction the double chain variant remains active (green) but will be inactivated by separation of hc and lc. Representative blots of brain lysate
from 3-month-old and 20-month-old Grn+/+ (wt) and Grn−/− (ko) mice probed for cathepsin D (CatD) (b, d) cathepsin B (CatB) (f, h) and cathepsin L (CatL)
(j, l). The molecular weight standards in kilo Daltons (kDa) are indicated on the left side of the blots. Quantification of blots for total cathepsin or maturation
variants normalized to Grn+/+ are shown as mean± SD. N= 5 mice per genotype (b, d, f, h, j, l). Statistical significance was set at *, p< 0.05; **, p< 0.01; and
***, p< 0.001; ns, not significant using an unpaired, two-tailed student’s t-test. In vitro enzyme activity of CatD, CatB and CatL in lysates of mouse brains used
for immunoblot analysis. Equal amounts of enzyme optimized brain lysates from Grn+/+ and Grn−/− (n= 3–5) mice were incubated with quenched
fluorogenic substrate (c, e, g, i, k, m). The increase of fluorescence signal was continuously measured and for a linear turnover time period normalized to
Grn+/+ set as 100% activity, mean± SD. Statistical significance was set at ***, p< 0.001 and ns, not significant using unpaired, two-tailed student’s t-test
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Grn+/+ MEF (Fig. 4a). In particular, during the first 24 h
protein degradation is elevated in Grn−/− MEF (Fig. 4a). El-
evated lysosomal protein turnover in PGRN deficient MEF
was also indicated by lower steady state levels of proteins
degraded by lysosomes such as APP and its CTF [54–57]







Fig. 3 PGRN loss alters maturation and elevates activity of cathepsins in MEF. a CatD expression and maturation in MEFpool Grn
+/+ (wt) and Grn−/− (ko)
shown in representative immunoblots. The pro-form CatDp, single chain form CatDsc, and heavy chain form CatDhc are indicated. Bar graphs show the
quantification of blots for total CatD or maturation variants normalized to Grn+/+. b CatD activity measured as cleavage of a quenched fluorogenic
substrate. The increase of fluorescence signal was continuously measured and during a linear turnover time period normalized to Grn+/+. Note that extracts
of CatD deficient MEF (Ctsdko) show no CatD activity and therefore confirm the specificity of the assay. c CatB expression and maturation in MEFpool Grn
+/+
(wt) and Grn−/− (ko) shown in representative immunoblots. The pro-form CatBp, single chain form CatBsc are indicated. Bar graphs show the quantification
of blots for total CatB or maturation variants normalized to Grn+/+. d CatB activity normalized to Grn+/+. e CatL expression and maturation in MEFpool Grn
+/+
(wt) and Grn−/− (ko) shown in representative immunoblots. The pro-form CatLp, single chain form CatLsc, heavy chain form CatLhc are indicated. Bar graphs
show the quantification of blots for total CatL or maturation variants normalized to Grn+/+. f CatL activity normalized to Grn+/+. g PGRN deficient MEF were
stably transfected with mouse PGRN (mGrn) and low PGRN expressing single cell clones (#5, #8) were analyzed for CatD, CatB and CatL in vitro activity.
Notice that very low expression of PGRN (#8) lowers cathepsin activities and thereby partially rescues the phenotype of the Grn−/− MEF, while the higher
expressing clone (#5) allows a full rescue for CatB and CatL. The molecular weight standards in kilo Daltons (kDa) are indicated on the left side of the blots. All
bar graphs are shown as mean± SD. Statistical significance was set at *, p< 0.05; **, p< 0.01; ***, p< 0.001; and ****, p< 0.0001 with ns as not significant
using a-f unpaired, two-tailed student’s t-test (n= 3), g one-way ANOVA with Dunnett’s post hoc test (n= 3–6)
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− MEF (Fig. 4c). To address the question whether
autophagy is altered by PGRN deficiency, we analyzed ubi-
quitin and the adapter protein p62/SQSTM1 levels in
Grn−/− MEF. Interestingly, we detect reduced levels of ubi-
quitinated proteins and p62 in Grn−/− MEF compared to
Grn+/+ MEF but no change in autophagy marker LC3I
and LC3II (Fig. 4d). Thus, we do not find evidence that
enhanced autophagosome formation contributes to the
enhanced lysosomal degradation in Grn−/− MEF (Fig. 4a).
Having observed an increased activity of cathepsins as
well as enhanced lysosomal protein degradation in
Grn−/− MEF, we asked whether PGRN or the proteo-
lytically generated granulin peptides are direct inhibi-
tors of lysosomal cathepsins. To do so, recombinant
PGRN, granulin peptides generated by elastase diges-
tion of PGRN or recombinant granulin E were added to
in vitro cathepsin activity assays using lysates derived
from Grn−/− MEF (Additional file 1: Figure S4). None
of the PGRN variants added to the in vitro assays had a
significant effect on proteolytic activity suggesting that
cathepsins may not be directly inhibited by an inter-
action with PGRN or the granulin peptides.
Selective impairment of lysosomal processing of
cathepsins in microglia upon PGRN deficiency
Enhanced lysosomal activity of cathepsins in Grn−/−
MEF and total brain homogenates of Grn−/− mice is
contradictory to impaired protein degradation and accu-
mulation of lipofuscin and NCL storage components
caused by PGRN deficiency. Therefore, we analyzed the
consequence of PGRN deficiency in microglia, which are
known to express more than 50-fold higher levels of Grn
mRNA as compared to neurons [58, 59]. We hypothe-





Fig. 4 Elevated lysosomal activity results in enhanced fast protein
degradation in Grn−/−MEF. a Turnover of 35S-methionine radiolabeled
proteins. MEF at 70–80% confluency were metabolically pulse-labeled with
35S-methionine/cysteine for 1 h, followed by indicated chase periods.
Radioactivity of 35S- labeled proteins at chase time point 0 h was set to
100% and remaining radioactive-labeled proteins at later chase points were
normalized to the initial radioactivity at time point 0 h. For statistical
analysis the unpaired, two-tailed student’s t-test was used to compare
Grn−/− to Grn+/+ MEF (n=5), (*, p<0.05). b APP holoprotein (APPholo) and
C-terminal fragments (APPCTF) detected by immunoblotting of MEFpool
Grn+/+ (wt) and Grn−/− (ko) lysates. The molecular weight standards in kilo
Daltons (kDa) are indicated on the left side of the blots. Bar graphs show
the quantification of the blots for APPholo and APPCTF normalized to Grn
+/+
(wt) as mean± SD. c Quantification of AppmRNA of MEFpool Grn
−/− (ko)
normalized to Grn+/+ (wt) as mean± SD. d Ubiquitin (Ub), p62, LC3-I and
LC3-II detected by immunoblotting of MEFpool Grn
+/+ (wt) and Grn−/− (ko)
lysates. Bar graphs show the quantification of the blots normalized to wt as
mean± SD. b-d For statistical analysis the unpaired, two-tailed student’s t-
test was used to compare ko to wt cells (n = 3) (*, p<0.05; **, p<0.01; ***,
p<0.001; ns, not significant)









Fig. 5 (See legend on next page.)
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effects in microglia, which could be different to the ma-
jority of the non-microglial brain cell population. First,
to confirm predominant PGRN protein expression in
microglia, we performed immunoblots on lysates of
acutely isolated microglia, astrocytes and neurons from
adult wildtype mouse brain (Fig. 5a). This fully con-
firmed that PGRN is most robustly expressed in micro-
glia (Fig. 5b). To address whether PGRN deficiency
results in cell autonomous alterations of lysosomal function
in microglia, we analyzed protein expression and matur-
ation of selected cathepsins in acutely isolated microglia.
Strikingly, microglia isolated from 3-month-old Grn−/−
mice show impaired maturation of cathepsins and an accu-
mulation of inactive pro-forms of CatD, CatB, CatL and
CatS (Fig. 5c, e, g, i). For CatB and CatL, the pro-form is
significantly elevated (Fig. 5e, g). The relative increase of
(See figure on previous page.)
Fig. 5 Cathepsin maturation is selectively impaired in Grn−/− microglia. a Schematic representation of the brain cell isolation using MACS
Technology (Miltenyi Biotec) b PGRN expression in acutely isolated microglia, astrocytes and neurons enriched fractions of 4- month-old wt mice
detected by immunoblotting. The identity of neural cell types was verified by detection of Iba1 for microglia, GFAP for astrocytes and Tuj1 for
neurons. c-i Cathepsin expression and maturation in the CD11b-positive, microglia enriched, fraction and the CD11b-negative, microglia depleted
cellular fraction isolated form cortices of brain from 3-month-old Grn+/+ (wt) and Grn−/− (ko) mice. Representative immunoblots for the cathepsin
expression of CatD (c, d), CatB (e, f), CatL (g, h) and for CatS (i) (only microglia enriched fraction). The molecular weight standards in kilo Daltons
(kDa) are indicated on the left side of all immunoblots. A dotted line in the blot indicates that samples of heterozygous mice were cut out, but
all samples were loaded on one gel. Quantification of immunoblots for total cathepsin or maturation variants pro-form (p), single chain (sc) and
heavy chain (hc) normalized to wt are shown as mean ± SD. For statistical analysis the unpaired, two-tailed student’s t-test was used to compare





Fig. 6 Cathepsins are elevated in the microglia depleted cell fraction of aged Grn−/− mice. a-d Cathepsin expression and maturation in the CD11b-positive,
microglia enriched, fraction and the CD11b-negative, microglia depleted cellular fraction isolated form cortices of brains from 12-month-old Grn+/+ (wt) and
Grn−/− (ko) mice. Representative immunoblots for the expression of CatD (a, b), CatB (c, d). The molecular weight standards in kilo Daltons (kDa) are indicated
on the left side of all immunoblots. A dotted line in the blot indicates that samples of heterozygous mice were cut out, but all samples were loaded on one
gel. Quantification of immunoblots for total cathepsin or pro-form (p), single chain (sc) and heavy chain (hc) normalized to wt are shown as mean± SD. For
statistical analysis the unpaired, two-tailed student’s t-test was used to compare ko to wt mice (n= 3–5) (*, p< 0.05; **, p< 0.01; ***, p< 0.001; ns, not
significant) (a-d)
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CatDp in Grn
−/− could not be quantified since CatDp can-
not be detected in Grn+/+ microglia. Despite a general in-
crease of pro-cathepsins, the levels of mature cathepsins
are differentially affected by the loss of PGRN. Thus, the
total protein level of CatD and the potentially active forms
CatDsc and CatDhc are significantly reduced in microglia of
Grn−/− (Fig. 5c). However a significantly reduced in vitro
activity of CatD could not be detected (Additional file 1:
Figure S5a). For the other analyzed cathepsins the total
level is unchanged (CatB, CatS) (Fig. 5e, i) or even elevated
(CatL) (Fig. 5g). In the microglia depleted fraction isolated
from 3-month-old mice, no significant differences of cathep-
sin maturation, expression level or activity between Grn−/−
and Grn+/+ can be observed (Fig. 5d, f, h; Additional file 1:
Figure S5a), whereas in the microglia depleted fraction of
12-month-old mice CatD is significantly elevated in Grn−/−
(Fig. 6b) which results in enhanced CatD activity (Additional
file 1: Figure S5b). However, in microglia of 12-month-old
Grn−/− mice altered expression levels of CatD and CatB are
not further enhanced but rather slightly reduced (Fig. 6a, c),
e.g. immature CatBp shifts from an almost 6-fold increase in
3-month-old mice to an 3-fold increase in 12-month-old
mice (Fig. 6c). In line with altered processed or reduced
lysosomal cathepsins specifically in microglia, LAMP1 and
saposin D accumulation occurred exclusively (LAMP1) or
more robust (saposin D) in the microglia enriched fraction
compared to the microglia depleted fraction isolated from
3-month-old mice (Fig. 7a-c).
Thus our data indicate that microglia and the
remaining neural cell populations show fundamentally
different lysosomal phenotypes upon PGRN deficiency.
Discussion
Accumulating evidence suggests that impaired lysosomal
protein degradation plays a major role in FTLD-TDP
[15]. Lysosomal dysfunction seems to be specifically as-
sociated with FTLD-TDP caused by GRN haploinsuffi-
ciency [18]. Furthermore total loss of PGRN leads to
NCL (CLN11) [3], a lysosomal storage disease with se-
vere neurodegeneration. However, it is still unknown if
and how PGRN affects lysosomal homeostasis. Based on
the selective expression of GRN in microglia (Fig. 5b)
[51, 58, 59], we now searched for cell autonomous and
non-cell autonomous deficits upon loss of PGRN.
We provide strong evidence that loss of PGRN select-
ively impairs lysosomal function in microglia. Microglia
isolated from 3-month-old Grn−/− mice showed strongly
reduced CatD levels compared to microglia isolated
from Grn+/+ mice, which surprisingly did not result in a
significantly reduced in vitro activity. However, impaired
maturation might not be reflected by the in vitro activity
assay since defective CatD maturation and catalytic ac-
tivity could be hidden by optimal in vitro conditions. In
addition, maturation of CatB, CatL and CatS was
impaired. In contrast, in the microglia depleted fraction,
isolated from the same 3-month-old Grn−/− mice, no al-
tered cathepsin expression or maturation was observed.
Furthermore, during ageing saposin D and LAMP1 ac-
cumulated earlier and to a higher extent in the microglia
enriched fraction than in the microglia depleted fraction.
Our finding that impaired maturation of lysosomal en-
zymes in microglia already occurs in early adulthood be-
fore other pathological hallmarks suggests that
lysosomal dysfunction may be a primary consequence
upon loss of PGRN expression. Thus, our findings sug-
gest a cell autonomous reduction of lysosomal function
caused by PGRN deficiency in microglia, which as a con-
sequence appears to culminate during ageing in a com-
pensatory upregulation of lysosomal activity selectively
in non-microglial cells. Indeed, in the microglia depleted





Fig. 7 Enhanced accumulation of lysosomal proteins in microglia of 3-
month-old Grn−/− mice. Representative blots of LAMP1 (a, b) and saposin
D (SapD) (c, d) in the CD11b-positive, microglia enriched fraction and the
CD11b-negative, microglia depleted fraction isolated form brain cortices of
3-month-old Grn+/+ (wt) and Grn−/− (ko) mice. A dotted line in the blot
indicates that samples of heterozygous mice were cut out, but all samples
were loaded on one gel. Data were normalized to the corresponding
mean value of wt mice and are shown as mean± SD. For statistical analysis
the unpaired, two-tailed student’s t-test was used to compare ko to wt
mice (n=4–5) (*, p<0.05; **, p<0.01; ***, p<0.001; ns, not significant)
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heavy chain are 2-fold and CatD in vitro activity is
2.5-fold elevated compared to Grn+/+ mice. Our findings
are supported by the observation that cultured neurons
from Grn−/− mice show enhanced lysosomal proteolysis
[51]. Moreover, in brain tissue of FTLD-TDP patients
CatD is accumulating in neurons [21]. In line with en-
hanced cathepsin expression in non-microglial cells,
mRNA, protein levels and in vitro activities of CatD,
CatB, and CatL were increased in total brain of aged
Grn−/− mice. Furthermore, in line with recent findings
[21, 38, 40, 51, 59, 60], a subset of lysosomal proteases
and membrane proteins were upregulated in 6- and
12-month-old Grn−/− mice. In addition to altered
cathepsin levels, we demonstrate altered proteolytic pro-
cessing and maturation of CatD, CatB, and CatL in the
microglia enriched fraction, total brain lysates and MEF
of Grn−/− mice. While in microglia proteolytic inactive
pro-forms accumulate, potentially active single chain or
heavy chain variants accumulate in total brain and MEF
in accordance with increased in vitro activity. For ex-
ample, robustly enhanced levels of the CatDhc variant
are observed in Grn−/− MEF which is in line with find-
ings by Tanaka et al. [21]. Previous research revealed en-
hanced [51, 59] as well reduced lysosomal enzyme
activities [38, 39] in various Grn−/− cells types or tissue.
Based on our findings, these discrepancies may be ex-
plained by different cell types analyzed, difficulties with
the determination of specific activities of lysosomal en-
zymes due to their complex proteolytic processing and
consequences for their proteolytic activity [53, 61]. Sin-
gle chain variants as well as dimeric variants of heavy
and light chain are catalytically active whereas separated
heavy and light chains are inactive [53, 61]. Since we
cannot determine the amount of active species, we can-
not calculate the specific activity. Indeed, in total brain
of Grn−/− mice the increase of CatD protein is much
stronger than the increase in enzyme activity which
might indicate reduced specific activity as previously
shown for CatD [38, 39]. However, it is unlikely that
PGRN directly affects the specific activity of lysosomal
proteases, because in our hands, adding PGRN, elastase
digested PGRN, or granulin E to the in vitro activity as-
says of CatD, CatB, and CatL did not alter their activity.
This might indicate that PGRN most likely modulates
maturation and turnover of cathepsins.
In MEF, enhanced cathepsin activities are reversible by
low expression levels of PGRN. Rescue of the lysosomal
phenotype of Grn−/− by a very minor amount of PGRN
is in line with recent data showing that low levels of
AAV-expressed neuronal PGRN are sufficient to rescue
Fig. 8 Schematic summary of differential effects of PGRN deficiency on brain cell types. Lysosomal impairment in microglia observed in young
Grn−/− mice result in enhanced lysosomal activity in non-microglial brain cells like neurons in aged Grn−/− mice. Basal lysosomal functions of
microglia and neurons are indicated in orange, changes to lower activity (yellow) in microglia or higher activity (red) in neurons or other non-
microglial brain cells are caused by PGRN deficiency and aging
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lysosomal phenotypes of Grn knockout mice [62]. More-
over, this also provides additional support for the lack of
lysosomal abnormalities in heterozygous, neuronal or in-
complete microglial Grn knockout mouse models [63, 64].
Finally, elevated catalytic activities of cathepsins result in
enhanced protein turnover in Grn−/− MEF, which indicates
enhanced protein degradation in lysosomes. In line with en-
hanced lysosomal degradation, levels of lysosomal targeted
proteins such as mature APP and its CTF are significantly
reduced in Grn−/− MEF while LC3I and LC3II levels are
unchanged. Only under cellular stress impaired autophagy
or altered autophagic flux has been reported for bone mar-
row derived macrophages (BMDM) [40].
The cell type dependent effects of PGRN deficiency in
microglial and non-microglial cells could be caused by
different lysosomal gene expression signatures in micro-
glia/monocytes compared to other brain cells. Microglia
not only express more and higher levels of lysosomal en-
zymes, they also express more and higher levels of lyso-
somal enzyme inhibitors. Thus regulation of lysosomal
activity might be more complex in microglia. Further
work needs to be done to elucidate how PGRN modu-
lates cathepsin activities and which role lysosomal gener-
ated granulins play [31, 32]. With this work we provide
strong evidence that PGRN plays a role as modulator of
lysosomal activity by affecting maturation of lysosomal
cathepsins. Such a function has been suggested for
granulin-like domains located at the C-terminus of
papain-like cysteine protease in plants [65–67]. Here,
the granulin domain might slow maturation of the pro-
tease. Furthermore, the granulin domain must be pro-
teolytically removed to allow full maturation [68, 69].
Finally, the divergent effects of PGRN deficiency in micro-
glial and non-microglial cells not only provide evidence
for differential cell autonomous and non-autonomous
activities of PGRN, but also suggest a crosstalk of
microglia with other cell types throughout the brain.
Interestingly, we [70] and others [71] previously
found that microglial loss-of-function mutations in
TREM2 affect energy metabolism throughout the en-
tire brain. Again, a rather small percentage of brain
cells seemed to influence metabolism throughout the
entire brain.
Conclusions
We conclude that PGRN deficiency leads to cell autono-
mous altered maturation and turnover of lysosomal ca-
thepsins with cell type dependent differences and
consequences. In particular in microglia, PGRN defi-
ciency results in accumulation of inactive cathepsin
pro-forms, while in other brain cells and in MEF, vari-
ants with increased catalytic activities were found. We
speculate that impaired lysosomal function in microglia
caused by PGRN deficiency already in young adults is
likely responsible for impaired protein degradation and
lipofuscin accumulation. With aging of Grn−/− mice,
non-microglial brain cells try to compensate decreased
protein degradation by microglia, with enhanced expres-
sion of selective cathepsins as shown for CatD, CatB and
CatL (Fig. 8).
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